Drug updated on 5/17/2024
Dosage Form | Tablet (oral; 600 mg of abacavir, 50 mg of dolutegravir, and 300 mg of lamivudine); PD Tablet (oral; 60 mg of abacavir, 5 mg of dolutegravir, and 30 mg of lamivudine) |
Drug Class | Integrase strand transfer inhibitors and nucleoside analogue reverse transcriptase inhibitors |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of HIV-1 infection in adults and in pediatric patients aged at least 3 months and weighing at least 6 kg.
Latest News
![loading GIF](/img/news-loading.gif)
Summary
- Abacavir, dolutegravir, and lamivudine (Triumeq) is indicated for the treatment of HIV-1 infection in adults and pediatric patients aged at least 3 months and weighing at least 6 kg.
- Information was derived from a study that was a Randomized Controlled Trial comparing Triumeq to another medication regimen consisting of bictegravir, emtricitabine, and tenofovir alafenamide.
- In terms of safety and effectiveness comparison between the two regimens for treating HIV-1 infection, both were found to be non-inferior with respect to achieving plasma HIV-1 RNA less than 50 copies per mL. Specifically, virological suppression was achieved by 88% of participants in the bictegravir group compared to 90% in the Triumeq group.
- Adverse events such as nausea were more common with Triumeq use (24%) when compared with its comparator drug combination (11%). Serious adverse events were comparable between groups, while no participants discontinued due to adverse effects in the bictegravir group versus a discontinuation rate of 2% due to such events within those using Triumeq.
- Drug-related adverse event reporting rates also favored usage of the bictegravir-based regimen over that involving abacavir/dolutegravir/lamivudine, reported by only about three-quarters as many users, that is, 28%, relative to those on this latter therapy who experienced these issues at an incidence rate closer to half, that is, 40%.
- The study population consisted mainly of adult individuals living with HIV who are free from hepatitis B virus infection or HLA-B*5701 negative status. This suggests that findings may be broadly applicable among similar demographic profiles, but detailed subgroup analyses based on demographics or comorbidities were not provided.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Triumeq (abacavir, dolutegravir, and lamivudine) Prescribing Information. | 2024 | ViiV Healthcare, Durham, NC |
Randomized Controlled Trials
Document Title | Sex Distribution | Year | Source |
---|---|---|---|
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. | 629Subjects F: 10% M: 90% | 2019 | The Lancet HIV |
Sex Distribution:
F:10%
M:90%
629Subjects
Year:
2019
Source:The Lancet HIV
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. | 2023 | National Institute of Health |
Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. | 2023 | National Institute of Health |
European AIDS clinical society guidelines v10.1 October 2020. | 2020 | European AIDS Clinical Society |